Merck KGaA reportedly considering generics sale
Germany's Merck KGaA is mulling the possible sale of its generics drug business, according to a news report. The unit could be worth about €4 billion and the money would help fund its acquisition of Switzerland's Serono as it focuses on developing new therapies. Any sale would likely be to financial investors, analysts note. The European drug company declined to comment on the report.
- here's the AFX report on Merck's plans
Related Articles:
Merck KGaA buying control of Serono. Report
Merck KGaA inks deal with China's Chi-Med. Report
Be the first to comment
More stories about Drug Development China analysts Serono Mergers and Acqusitions Generics darmstadt germany Switzerland Merck KgAA
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
